Annexon (ANNX) Enterprise Value (2019 - 2026)
Annexon (ANNX) posted quarterly Enterprise Value of -$225.0 million for Q1 2026, up 15.0% year-over-year from -$195.7 million in Q1 2025, and up 4.78% quarter-over-quarter from -$236.3 million in Q4 2025.
Annexon (ANNX) Enterprise Value (2019 - 2026) Analysis & Trends
Annexon's Enterprise Value history runs 8 years deep, the most recent figure standing at -$225.0 million for Q1 2026.
- In Q1 2026, Enterprise Value rose 15.0% year-over-year to -$225.0 million; the TTM figure through Mar 2026 stood at -$225.0 million (up 15.0% YoY), while the FY2025 annual figure was -$236.3 million, up 24.51% from the prior year.
- Enterprise Value for Q1 2026 stood at -$225.0 million, up from -$236.3 million in the prior quarter.
- The five-year high for Enterprise Value was -$94.4 million in Q1 2022, with the low at -$369.7 million in Q2 2024.
- The 5-year median for Enterprise Value is -$236.3 million (2025), against an average of -$239.4 million.
- The sharpest annual moves came in 2022 and 2023: Enterprise Value soared 71.1% in 2022, then sank 142.76% in 2023.
- Annexon's Enterprise Value stood at -$243.7 million in 2022, then declined by 7.0% to -$260.7 million in 2023, then retreated by 20.06% to -$313.0 million in 2024, then rose by 24.51% to -$236.3 million in 2025, then grew by 4.78% to -$225.0 million in 2026.
- Business Quant data shows ANNX's Enterprise Value at -$225.0 million in Q1 2026, -$236.3 million in Q4 2025, and -$188.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Annexon | 1.00 Bn | 1.00 Bn | - | -209.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -209.24 Mn |
| Mar 31, 2026 | -225.03 Mn |
| Dec 31, 2025 | -236.33 Mn |
| Sep 30, 2025 | -188.72 Mn |
| Jun 30, 2025 | -227.02 Mn |
| Mar 31, 2025 | -264.73 Mn |
| Dec 31, 2024 | -313.05 Mn |
| Sep 30, 2024 | -341.15 Mn |
| Jun 30, 2024 | -369.73 Mn |
| Mar 31, 2024 | -265.98 Mn |
| Dec 31, 2023 | -260.75 Mn |
| Sep 30, 2023 | -166.30 Mn |
| Jun 30, 2023 | -193.97 Mn |
| Mar 31, 2023 | -229.20 Mn |
| Dec 31, 2022 | -243.69 Mn |
| Sep 30, 2022 | -270.55 Mn |
| Jun 30, 2022 | -178.63 Mn |
| Mar 31, 2022 | -94.41 Mn |
| Dec 31, 2021 | -243.88 Mn |
| Sep 30, 2021 | -271.37 Mn |